




PHARMACEUTICAL 2017

Mirati Therapeutics Inc.
Rank 200 of 292





RealRate

PHARMACEUTICAL 2017

Mirati Therapeutics Inc.
Rank 200 of 292



The relative strengths and weaknesses of Mirati Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Mirati Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 47% points. The greatest weakness of Mirati Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 117% points.

The company's Economic Capital Ratio, given in the ranking table, is -0.099%, being 3.0% points below the market average of 2.9%.

Input Variable	Value in 1000 USD
Assets, Current	59,555
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	15,002
Liabilities, Non-Current	133
Other Assets	3,260
Other Compr. Net Income	-25
Other Expenses	0
Other Liabilities	0
Other Net Income	661
Other Revenues	0
Property and Equipment	629
Research and Development	68,487
Selling, General and Administrative Expense	15,292

Output Variable	Value in 1000 USD
Assets	63,444
Liabilities	15,135
Expenses	83,779
Revenues	0
Stockholders Equity	48,309
Net Income	-83,118
Comprehensive Net Income	-83,130
Economic Capital Ratio	-0.099%